Alison Moore Ph.D.
Net Worth
Last updated:
What is Alison Moore Ph.D. net worth?
The estimated net worth of Dr. Alison Moore Ph.D. is at least $11,906,938 as of 15 Mar 2022. He owns shares worth $128,860 as insider, has earned $7,818,078 from insider trading and has received compensation worth at least $3,960,000 in Allogene Therapeutics, Inc..
What is the salary of Alison Moore Ph.D.?
Dr. Alison Moore Ph.D. salary is $660,000 per year as Chief Technical Officer in Allogene Therapeutics, Inc..
How old is Alison Moore Ph.D.?
Dr. Alison Moore Ph.D. is 58 years old, born in 1967.
What stocks does Alison Moore Ph.D. currently own?
As insider, Dr. Alison Moore Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | Chief Technical Officer | 120,430 | $1.07 | $128,860 |
What does Allogene Therapeutics, Inc. do?
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Alison Moore Ph.D. insider trading
Allogene Therapeutics, Inc.
Dr. Alison Moore Ph.D. has made 15 insider trades between 2019-2022, according to the Form 4 filled with the SEC. Most recently he sold 8,698 units of ALLO stock worth $66,392 on 15 Mar 2022.
The largest trade he's ever made was exercising 48,828 units of ALLO stock on 3 Jun 2019. As of 15 Mar 2022 he still owns at least 120,430 units of ALLO stock.
Allogene Therapeutics key executives
Allogene Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Alison Moore Ph.D. (58) Chief Technical Officer
- Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. (76) Co-Founder & Executive Chairman
- Dr. David D. Chang M.D., Ph.D. (65) Co-Founder, Pres, Chief Executive Officer & Director
- Dr. Eric Thomas Schmidt Ph.D. (55) Chief Financial Officer
- Dr. Rafael G. Amado (61) Chief Medical Officer and Executive Vice President of R&D
- Mr. Joshua A. Kazam (48) Co-Founder & Director
- Mr. Veer Bhavnagri (42) Gen. Counsel & Compliance Officer